How Zolbetuximab (Vyloy, Zolbetuximab) works

Zolbetuximab (Vyloy, Zolbetuximab) is an advanced anti-CLDN-18.2 monoclonal antibody designed for use in combination with chemotherapy to treat patients with certain types of gastric cancer. This innovative drug belongs to the chimeric immunoglobulin G1 (IgG1) monoclonal antibody class and can precisely target the Claudin 18.2 (CLDN18.2) transmembrane protein that is abnormally expressed in gastric cancer and gastroesophageal cancer. Under normal circumstances, CLDN18.2 is present in the gastric mucosa, but the occurrence of cancer causes it to be exposed on the surface of cancer cells, making it a target for zotuximab.

Once inside the body, zotuximab quickly binds to CLDN18.2 on the surface of cancer cells, triggering the immune system's powerful destruction of cancer cells by activating antibody-dependent cytotoxicity and complement-dependent cytotoxicity mechanisms, effectively preventing the proliferation of cancer cells. The affirmation of its efficacy is due to the excellent results of two key clinical trials-SPOTLIGHT and GLOW.

InSPOTLIGHT trial, zotuximab combined with mFOLFOX6 chemotherapy regimen as first-line treatment significantly prolonged the progression-free survival (PFS) and overall survival (OS) of patients with HER2-negative and CLDN18.2-positive locally advanced inoperable or metastatic gastric cancer. Compared with placebo, the risk of disease progression or death in the treatment group was reduced by 24.9%, and the median PFS reached 10.61 months.

Similarly, in theGLOW trial, zotuximab combined with CAPOX chemotherapy also showed excellent efficacy. The regimen not only significantly reduced the risk of disease progression or death (31.3% reduction), it also extended patients' median PFS to 8.21 months and significantly reduced the threat of mortality (22.9% reduction).

Although zotuximab may cause some adverse events during treatment, such as nausea, vomiting, anorexia, neutropenia, and weight loss, most of these adverse events can be alleviated and controlled by some means. Therefore, patients can safely be treated with zotuximab under the guidance and monitoring of a physician.

In short, zotuximab (Vyloy, Zolbetuximab), as an advanced anti-CLDN-18.2 monoclonal antibody, has shown great potential and efficacy in the treatment of gastric cancer. Its precise targeting, dual mechanism of action and excellent clinical trial results make zotuximab an important option in the treatment of gastric cancer.